Efficacy and safety of intravenous ferric carboxymaltose in iron deficiency anemia; Real-life data from Turkey, a single center experience

Abstract

The most common reason of anemia is iron deficiency. Oral iron preparations are the first and most preferred method of treatment of iron deficiency anemia (IDA). In cases where Hb levels need to be increased rapidly, intravenous iron treatment gives more favorable results. Ferric carboxymaltose (FCM) is the most recent formulation developed to reduce the problem of anaphylaxis and has reached a very wide usage rate in a short time. In this study, we wanted to show the efficacy and safety of this treatment in patients diagnosed with IDA and treated with FCM in our clinic. In this study, 103 patients older than 18 years old who were diagnosed with IDA and treated with FCM, in our clinic, between January 2020 and December 2020 were included in the study. A total of 103 patients were evaluated. In the tests performed one month and two months after FCM use, an increase was seen as the following; the median of hemoglobin (Hb) level was 2.6 and 3.7 gr/dL, the median of hematocrit (Hct) level was 6% and 10%, the median of transferrin saturation (TS) was 17% and 18%, and the median of ferritin level was 85 and 48 ng/mL, respectively. When the Hb, Hct, TS and ferritin values were compared basal and after FCM treatment, statistically significant increase was found (p [Med-Science 2021; 10(2.000): 422-6]

Keywords

• iron deficiency anemia
• hemoglobin
• ferritin
• ferric carboxymaltose